277 related articles for article (PubMed ID: 20506558)
1. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.
Zahr N; Arnaud L; Marquet P; Haroche J; Costedoat-Chalumeau N; Hulot JS; Funck-Brentano C; Piette JC; Amoura Z
Arthritis Rheum; 2010 Jul; 62(7):2047-54. PubMed ID: 20506558
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study.
Roland M; Barbet C; Paintaud G; Magdelaine-Beuzelin C; Diot E; Halimi JM; Lebranchu Y; Nivet H; Büchler M
Lupus; 2009 Apr; 18(5):441-7. PubMed ID: 19318398
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.
Sagcal-Gironella AC; Fukuda T; Wiers K; Cox S; Nelson S; Dina B; Sherwin CM; Klein-Gitelman MS; Vinks AA; Brunner HI
Semin Arthritis Rheum; 2011 Feb; 40(4):307-13. PubMed ID: 20655577
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D
Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
[TBL] [Abstract][Full Text] [Related]
6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
9. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
10. Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
J Clin Pharm Ther; 2012 Apr; 37(2):217-20. PubMed ID: 21517926
[TBL] [Abstract][Full Text] [Related]
11. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
Daleboudt GM; Reinders ME; den Hartigh J; Huizinga TW; Rabelink AJ; de Fijter JW; Berger SP
Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
[TBL] [Abstract][Full Text] [Related]
13. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.
Djabarouti S; Breilh D; Duffau P; Lazaro E; Greib C; Caubet O; Saux MC; Pellegrin JL; Viallard JF
Arthritis Res Ther; 2010; 12(6):R217. PubMed ID: 21176194
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring.
Woillard JB; Bader-Meunier B; Salomon R; Ranchin B; Decramer S; Fischbach M; Berard E; Guigonis V; Harambat J; Dunand O; Tenenbaum J; Marquet P; Saint-Marcoux F
Br J Clin Pharmacol; 2014 Oct; 78(4):867-76. PubMed ID: 24697955
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
[TBL] [Abstract][Full Text] [Related]
17. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil.
Neumann I; Fuhrmann H; Fang IF; Jaeger A; Bayer P; Kovarik J
Nephrol Dial Transplant; 2008 Nov; 23(11):3514-20. PubMed ID: 18586766
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study.
Nannini C; Crowson CS; Matteson EL; Moder KG
Lupus; 2009 Apr; 18(5):394-9. PubMed ID: 19318390
[TBL] [Abstract][Full Text] [Related]
19. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
